BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18688571)

  • 1. Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
    Dall'oglio S; D'Amico A; Pioli F; Gabbani M; Pasini F; Passarin MG; Talacchi A; Turazzi S; Maluta S
    J Neurooncol; 2008 Dec; 90(3):315-9. PubMed ID: 18688571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
    Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
    J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
    Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
    J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
    Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
    J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
    Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
    J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
    Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
    Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
    Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
    Abacioglu U; Caglar HB; Yumuk PF; Akgun Z; Atasoy BM; Sengoz M
    J Neurooncol; 2011 Jul; 103(3):585-93. PubMed ID: 20878446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
    Broniscer A; Chintagumpala M; Fouladi M; Krasin MJ; Kocak M; Bowers DC; Iacono LC; Merchant TE; Stewart CF; Houghton PJ; Kun LE; Ledet D; Gajjar A
    J Neurooncol; 2006 Feb; 76(3):313-9. PubMed ID: 16200343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
    Combs SE; Bruckner T; Mizoe JE; Kamada T; Tsujii H; Kieser M; Debus J
    Radiother Oncol; 2013 Jul; 108(1):132-5. PubMed ID: 23932193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
    Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
    J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-schedule dose-dense temozolomide in refractory gliomas.
    Berrocal A; Perez Segura P; Gil M; Balaña C; Garcia Lopez J; Yaya R; Rodríguez J; Reynes G; Gallego O; Iglesias L;
    J Neurooncol; 2010 Feb; 96(3):417-22. PubMed ID: 19669096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
    Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
    Gupta T; Mohanty S; Moiyadi A; Jalali R
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.